| ［1］ |
Zhang X, Cai L, Zhao S, et al. CX⁃F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy［J］. Biochem Pharmacol, 2019,168:14⁃25. doi: 10.1016/j.bcp.2019.06.014.
|
| ［2］ |
Parmenter TJ, Kleinschmidt M, Kinross KM, et al. Response of BRAF⁃mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis［J］. Cancer Discov, 2014,4（4）:423⁃433. doi: 10.1158/2159⁃8290.CD⁃13⁃0440.
|
| ［3］ |
高天文, 郭伟楠. 中国黑素瘤研究进展与新治疗策略［J］. 中华皮肤科杂志, 2021,54（1）:27⁃32. doi: 10.35541/cjd.20200560.
|
| ［4］ |
Khan A, Valli E, Lam H, et al. Targeting metabolic activity in high⁃risk neuroblastoma through Monocarboxylate Transporter 1 （MCT1） inhibition［J］. Oncogene, 2020,39（17）:3555⁃3570. doi: 10.1038/s41388⁃020⁃1235⁃2.
|
| ［5］ |
Kamenisch Y, Baban T, Schuller W, et al. UVA⁃irradiation induces melanoma invasion via the enhanced Warburg effect［J］. J Invest Dermatol, 2016,136（9）:1866⁃1875. doi: 10.1016/j.jid.2016.02.815.
|
| ［6］ |
Ubellacker JM, Tasdogan A, Ramesh V, et al. Lymph protects metastasizing melanoma cells from ferroptosis［J］. Nature, 2020,585（7823）:113⁃118. doi: 10.1038/s41586⁃020⁃2623⁃z.
|
| ［7］ |
Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment［J］. Semin Cancer Biol, 2019,59:236⁃250. doi: 10.1016/j.semcancer.2019.08.002.
|
| ［8］ |
Feichtinger RG, Lang R, Geilberger R, et al. Melanoma tumors exhibit a variable but distinct metabolic signature［J］. Exp Dermatol, 2018,27（2）:204⁃207. doi: 10.1111/exd.13465.
|
| ［9］ |
Scott DA, Richardson AD, Filipp FV, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect［J］. J Biol Chem, 2011,286（49）:42626⁃42634. doi: 10.1074/jbc.M111.282046.
|
| ［10］ |
Luís R, Brito C, Pojo M. Melanoma metabolism: cell survival and resistance to therapy［J］. Adv Exp Med Biol, 2020,1219:203⁃223. doi: 10.1007/978⁃3⁃030⁃34025⁃4_11.
|
| ［11］ |
Haq R, Shoag J, Andreu⁃Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF［J］. Cancer Cell, 2013,23（3）:302⁃315. doi: 10.1016/j.ccr.2013.02.003.
|
| ［12］ |
Sensi M, Nicolini G, Petti C, et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single⁃cell level in the same human melanoma［J］. Oncogene, 2006,25（24）:3357⁃3364. doi: 10.1038/sj.onc.1209379.
|
| ［13］ |
Chae YC, Vaira V, Caino MC, et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming［J］. Cancer Cell, 2016,30（2）:257⁃272. doi: 10.1016/j.ccell.2016.07.004.
|
| ［14］ |
Neagu M. Metabolic traits in cutaneous melanoma［J］. Front Oncol, 2020,10:851. doi: 10.3389/fonc.2020.00851.
|
| ［15］ |
Li Z, Liu J, Que L, et al. The immunoregulatory protein B7⁃H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway［J］. J Cancer, 2019,10（23）:5770⁃5784. doi: 10.7150/jca.29838.
|
| ［16］ |
Dang CV, Le A, Gao P. MYC⁃induced cancer cell energy metabolism and therapeutic opportunities［J］. Clin Cancer Res, 2009,15（21）:6479⁃6483. doi: 10.1158/1078⁃0432.CCR⁃09⁃0889.
|
| ［17］ |
Zeller KI, Jegga AG, Aronow BJ, et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets［J］. Genome Biol, 2003,4（10）:R69. doi: 10.1186/gb⁃2003⁃4⁃10⁃r69.
|
| ［18］ |
Ruby KN, Liu CL, Li Z, et al. Diagnostic and prognostic value of glucose transporters in melanocytic lesions［J］. Melanoma Res, 2019,29（6）:603⁃611. doi: 10.1097/CMR.0000000000000626.
|
| ［19］ |
Koch A, Ebert EV, Seitz T, et al. Characterization of glycolysis⁃related gene expression in malignant melanoma［J］. Pathol Res Pract, 2020,216（1）:152752. doi: 10.1016/j.prp.2019.152752.
|
| ［20］ |
Koch A, Lang SA, Wild PJ, et al. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells［J］. Oncotarget, 2015,6（32）:32748⁃32760. doi: 10.18632/oncotarget. 4977.
|
| ［21］ |
Burián Z, Ladányi A, Barbai T, et al. Selective inhibition of HIF1α expression by ZnSO4 has antitumoral effects in human melanoma［J］. Pathol Oncol Res, 2020,26（2）:673⁃679. doi: 10.1007/s12253⁃018⁃00573⁃1.
|
| ［22］ |
Corazao⁃Rozas P, Guerreschi P, Jendoubi M, et al. Mitochondrial oxidative stress is the Achille′s heel of melanoma cells resistant to Braf⁃mutant inhibitor［J］. Oncotarget, 2013,4（11）:1986⁃1998. doi: 10.18632/oncotarget.1420.
|
| ［23］ |
Wang L, Leite de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug⁃resistant melanoma with therapeutic potential［J］. Cell, 2018,173（6）:1413⁃1425.e14. doi: 10.1016/j.cell.2018.04.012.
|
| ［24］ |
Avagliano A, Fiume G, Pelagalli A, et al. Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment［J］. Front Oncol, 2020,10:722. doi: 10.3389/fonc.2020.00722.
|
| ［25］ |
Vashisht Gopal YN, Gammon S, Prasad R, et al. A novel mitochondrial inhibitor blocks MAPK Pathway and overcomes MAPK inhibitor resistance in melanoma［J］. Clin Cancer Res, 2019,25（21）:6429⁃6442. doi: 10.1158/1078⁃0432.CCR⁃19⁃0836.
|
| ［26］ |
Bizzozero L, Cazzato D, Cervia D, et al. Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia⁃associated transcription factor signalling pathway［J］. Cell Death Differ, 2014,21（4）:507⁃520. doi: 10. 1038/cdd.2013.173.
|
| ［27］ |
Coazzoli M, Napoli A, Roux⁃Biejat P, et al. Acid sphingomyelinase downregulation enhances mitochondrial fusion and promotes oxidative metabolism in a mouse model of melanoma［J］. Cells, 2020,9（4）:848. doi: 10.3390/cells9040848.
|
| ［28］ |
Tasdogan A, Faubert B, Ramesh V, et al. Metabolic heterogeneity confers differences in melanoma metastatic potential［J］. Nature, 2020,577（7788）:115⁃120. doi: 10.1038/s41586⁃019⁃1847⁃2.
|
| ［29］ |
Kfoury A, Armaro M, Collodet C, et al. AMPK promotes survival of c⁃Myc⁃positive melanoma cells by suppressing oxidative stress［J］. EMBO J, 2018,37（5）:e97673. doi: 10.15252/embj.201797673.
|
| ［30］ |
Lee CK, Jeong SH, Jang C, et al. Tumor metastasis to lymph nodes requires YAP⁃dependent metabolic adaptation［J］. Science, 2019,363（6427）:644⁃649. doi: 10.1126/science.aav0173.
|
| ［31］ |
Magtanong L, Ko PJ, To M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis⁃resistant cell state［J］. Cell Chem Biol, 2019,26（3）:420⁃432.e9. doi: 10.1016/j.chembiol. 2018.11.016.
|
| ［32］ |
Raica M, Jitariu AA, Cimpean AM. Lymphangiogenesis and anti⁃lymphangiogenesis in cutaneous melanoma［J］. Anticancer Res, 2016,36（9）:4427⁃4435. doi: 10.21873/anticanres.10986.
|
| ［33］ |
Garmy⁃Susini B, Avraamides CJ, Desgrosellier JS, et al. PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes［J］. Proc Natl Acad Sci U S A, 2013,110（22）:9042⁃9047. doi: 10.1073/pnas.1219603110.
|
| ［34］ |
Garmy⁃Susini B, Avraamides CJ, Schmid MC, et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis［J］. Cancer Res, 2010,70（8）:3042⁃3051. doi: 10.1158/0008⁃5472.CAN⁃09⁃3761.
|
| ［35］ |
Cortez A, Josefsson A, McCarty G, et al. Evaluation of ［（225）Ac］Ac⁃DOTA⁃anti⁃VLA⁃4 for targeted alpha therapy of metastatic melanoma［J］. Nucl Med Biol, 2020,88⁃89:62⁃72. doi: 10.1016/j.nucmedbio.2020.07.006.
|
| ［36］ |
Baumann F, Leukel P, Doerfelt A, et al. Lactate promotes glioma migration by TGF⁃beta2⁃dependent regulation of matrix metalloproteinase⁃2［J］. Neuro Oncol, 2009,11（4）:368⁃380. doi: 10.1215/15228517⁃2008⁃106.
|
| ［37］ |
Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28⁃mediated Akt⁃dependent and independent pathways［J］. J Immunol, 2008,180（7）:4476⁃4486. doi: 10.4049/jimmunol.180.7.4476.
|
| ［38］ |
Najjar YG, Menk AV, Sander C, et al. Tumor cell oxidative metabolism as a barrier to PD⁃1 blockade immunotherapy in melanoma［J］. JCI Insight, 2019,4（5）:e124989. doi: 10.1172/jci.insight.124989.
|
| ［39］ |
Kim SH, Roszik J, Grimm EA, et al. Impact of l⁃arginine metabolism on immune response and anticancer immunotherapy［J］. Front Oncol, 2018,8:67. doi: 10.3389/fonc.2018.00067.
|
